Parabilis (PBLS) to Accelerate Global Clinical Trials with $670 Million Mega-Funding in June, Including Zolucatetide
Key Players in the Mega-Funding and Parabilis' Record-Breaking IPO
In June 2026, the global biotech market witnessed significant fundraising activity. Parabilis Medicines (PBLS) achieved a record-breaking IPO, raising $670 million, the largest venture-backed biotech IPO in history. These funds will be invested in developing its proprietary Helicon™ peptide platform, designed to target previously undruggable proteins. Its lead pipeline candidate, zolucatetide, a beta-catenin inhibitor, is set to enter a global Phase 3 clinical trial in the first half of 2027 for the treatment of desmoid tumors, generating considerable investor interest.
Innovative Series Funding in Cellular Rejuvenation and Ophthalmology
This month's private funding round saw NewLimit, a leader in epigenetic reprogramming technology, secure $435 million in Series C funding. The company has discovered a substance that reverses the age of human hepatocytes and is preparing for its first clinical trial (Phase 1) in 2027. Ollin Biosciences also secured $330 million in Series B funding to advance its global Phase 3 clinical trial for OLN324, an ophthalmic treatment. OLN324, targeting wet AMD, has demonstrated superior efficacy compared to the standard of care, making it a promising market contender.
Capital Concentrates on Promising Pipelines for Rare Diseases and Cardiovascular Treatments
Large-scale capital is also being selectively directed towards promising pipelines in rare diseases and cardiovascular fields. Beren Therapeutics raised $300 million to support the commercial launch of adrabetadex, a treatment for Niemann-Pick disease type C (NPC). Adrabetadex has received FDA Priority Review and is on track for a PDUFA target action date in November 2026. Kardigan (KARD), a cardiovascular specialist, successfully completed a $400 million IPO, securing the resources to rapidly expand its late-stage clinical assets, including danicamtiv, an oral cardiac myosin activator.
Securing Funding for Late-Stage Clinical Pipelines and Market Re-evaluation
This influx of capital provides promising biotechs with the financial runway to continue clinical trials uninterrupted. Enliven Therapeutics (ELVN) completed a $400 million public offering to accelerate the Phase 3 trial of ELVN-001, a treatment for chronic myeloid leukemia (CML), securing funding for clinical research through 2029. Mineralys Therapeutics (MLYS) also secured $150 million to support Phase 2/3 trials of lorundrostat, a treatment for hypertension. This is driving a re-evaluation of technology values across the industry.
The selective allocation of capital within the global biotech sector, exemplified by Parabilis' (PBLS) $670 million IPO and NewLimit's $435 million funding, is focused on validated platform technologies and late-stage clinical pipelines. In the short term, Beren Therapeutics' adrabetadex, with its FDA PDUFA review expected in November 2026, will serve as an immediate indicator of investor sentiment in the rare and orphan disease market. In the medium to long term, Ollin's OLN324 is poised to compete directly with established treatments like Regeneron's Eylea in the wet AMD market. Furthermore, Enliven's ELVN-001 has the potential to reshape the treatment paradigm for chronic myeloid leukemia (CML), depending on the results of its pivotal Phase 3 trial. Ultimately, this mega-funding round will accelerate the commercialization of innovative therapies and encourage institutional investors to increase their allocation to late-stage clinical assets.
Source: Labiotech (rss)
https://www.labiotech.eu/in-depth/biotech-funding-rounds-june-2026/